Egrx News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Egrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Egrx Today - Breaking & Trending Today
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Free Report) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $7.47 and traded as low as $4.57. Eagle Pharmaceuticals shares last traded at $4.69, with a volume of 161,336 shares changing hands. Eagle Pharmaceuticals Stock Up 2.1 […] ....
Brandes Investment Partners LP boosted its holdings in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Free Report) by 34.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,134,363 shares of the specialty pharmaceutical company’s stock after buying an additional 293,276 shares during the period. […] ....
Brandes Investment Partners LP grew its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Free Report) by 34.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,134,363 shares of the specialty pharmaceutical company’s stock after buying an additional 293,276 shares […] ....
9258 Wealth Management LLC reduced its holdings in The Gabelli Healthcare & Wellness Trust (NYSE:GRX – Free Report) by 2.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,532 shares of the investment management company’s stock after selling 1,375 shares during the […] ....
Smith Graham & Co. Investment Advisors LP increased its position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Free Report) by 1.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 273,099 shares of the specialty pharmaceutical company’s stock […] ....